Stocks
Alnylam Pharmaceuticals (ALNY) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -427.5% | -156.5% | -84.0% | -86.2% | -12.5% | -7.26% | ||
| Changes by years, y/y, % | +688pp | +271pp | +72pp | -2pp | +74pp | -59.3% | |||
Alnylam Pharmaceuticals. EBITDA margin, %
Alnylam Pharmaceuticals. EBITDA margin, changes, pp
Alnylam Pharmaceuticals (ALNY) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | 24.2% | -23.4% | -6.05% | 9.64% | -18.3% | -7.26% | |
| Changes by years, y/y, % | +113pp | +29pp | +39pp | +86pp | -43pp | |||
| Changes by quarters, q/q, % | +101pp | -48pp | +17pp | +16pp | -28pp | |||
